^
    1d
    Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2) (clinicaltrials.gov)
    P3, N=430, Active, not recruiting, Novartis Pharmaceuticals | Trial completion date: Dec 2027 --> Jun 2027
    Trial completion date
    |
    Jakafi (ruxolitinib) • pelabresib (DAK539)
    2d
    COV-BARRIER: A Study of Baricitinib (LY3009104) in Children With COVID-19 (clinicaltrials.gov)
    P3, N=6, Terminated, Eli Lilly and Company | N=24 --> 6 | Recruiting --> Terminated; Study terminated due to an inability to enroll participants.
    Enrollment change • Trial termination
    3d
    Ruxolitinib for Early Lung Dysfunction After Hematopoietic Stem Cell Transplant (clinicaltrials.gov)
    P2, N=40, Recruiting, Children's Hospital Medical Center, Cincinnati | Trial completion date: Nov 2025 --> Nov 2028 | Trial primary completion date: Nov 2025 --> Nov 2028
    Trial completion date • Trial primary completion date
    |
    Jakafi (ruxolitinib)
    3d
    First-Line Jaktinib for Acute Graft-Versus-Host Disease (aGVHD) (clinicaltrials.gov)
    P1/2, N=35, Recruiting, First Affiliated Hospital of Zhejiang University
    New P1/2 trial
    3d
    Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis (clinicaltrials.gov)
    P2, N=20, Recruiting, Fred Hutchinson Cancer Center | Suspended --> Recruiting
    Enrollment open
    |
    cyclophosphamide • melphalan • fludarabine IV • Inrebic (fedratinib)
    3d
    NTRK1-3 fusions in sarcomas: prevalence, significance, and clinical implications - a systematic review. (PubMed, Future Oncol)
    Larotrectinib was used in 142 patients, demonstrating an 83.80% response rate, with low mortality (2.82%) and recurrence (2.11%) rates. Entrectinib had a lower response rate of 63.64%. We confirm the rarity of NTRK1-3 fusions in sarcomas. TRK inhibitors show high efficacy in sarcomas, emphasizing the necessity of genomic testing in all cases.Protocol registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD42024563594.
    Review • Journal
    |
    NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • ETV6 (ETS Variant Transcription Factor 6) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    NTRK positive • NTRK fusion
    |
    Vitrakvi (larotrectinib) • Rozlytrek (entrectinib)
    4d
    VEXAS syndrome mimicking relapsing polychondritis: A case report (PubMed, Beijing Da Xue Xue Bao Yi Xue Ban)
    Notwithstanding substantial concerns about thrombotic risk due to positive phospholipid antibodies in the context of ruxolitinib treatment, thrombotic events were avoided with patient compliance to low-dose aspirin therapy. This case highlighted that the male patients aged over 50 years presenting with chondritis, refractory autoinflammatory manifestations, and/or unexplained hematological abnormalities, clinicians should consider bone marrow evaluation and UBA1 gene testing to promptly identify VEXAS syndrome, enabling early personalized treatment and improved outcomes.
    Journal
    |
    IL6 (Interleukin 6) • CRP (C-reactive protein)
    |
    Jakafi (ruxolitinib) • aspirin
    4d
    Baricitinib Versus Azathioprine in Patients With Moderate-to-Severe Atopic Dermatitis (clinicaltrials.gov)
    P=N/A, N=40, Completed, Mazandaran University of Medical Sciences | Active, not recruiting --> Completed | Trial completion date: Jun 2025 --> Nov 2025
    Trial completion • Trial completion date
    4d
    Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren Disease (clinicaltrials.gov)
    P2, N=60, Recruiting, National Institute of Dental and Craniofacial Research (NIDCR)
    New P2 trial
    |
    tofacitinib
    4d
    Dramatic Response to Entrectinib in a Rare Glioneuronal Tumor Harboring an NTRK2 Fusion. (PubMed, Oncologist)
    This case highlights the essential role of DNA methylation profiling in resolving diagnostic ambiguity and guiding targeted treatment in CNS tumors. It further supports the potential efficacy of entrectinib in NTRK fusion-positive glioneuronal tumors.
    Journal
    |
    NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • ATRX (ATRX Chromatin Remodeler) • KANK1 (KN Motif And Ankyrin Repeat Domains 1) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    NTRK positive • NTRK fusion
    |
    Rozlytrek (entrectinib)
    4d
    Tofacitinib in Recurrent GBM Patients (clinicaltrials.gov)
    P3, N=17, Active, not recruiting, University of Texas Southwestern Medical Center | Trial primary completion date: Jun 2026 --> Jun 2025
    Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • MGMT (6-O-methylguanine-DNA methyltransferase)
    |
    EGFR amplification • IDH wild-type
    |
    tofacitinib
    4d
    STK405759 targets microtubules, modulates STAT1, and enhances ruxolitinib efficacy in myeloproliferative neoplasms. (PubMed, Am J Cancer Res)
    Treatment also decreased VEGF secretion in both monocultures and HS-5 stromal co-cultures and induced IL-1β in co-cultures. These findings demonstrate that STK405759 exerts potent cytotoxic activity, disrupts microtubules, modulates STAT1 signaling, reduces VEGF secretion, and induces a distinct cytokine profile, while synergizing with ruxolitinib, supporting its further preclinical development as a potential therapeutic strategy in myeloproliferative neoplasms.
    Journal
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • JAK2 (Janus kinase 2) • STAT1 (Signal Transducer And Activator Of Transcription 1) • IL1B (Interleukin 1, beta) • ANXA5 (Annexin A5)
    |
    Jakafi (ruxolitinib)